Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice

Novel drugs have revolutionized multiple myeloma therapy in the last 20 years, with median survival that has doubled to up to 8–10 years. The introduction of therapeutic strategies, such as consolidation and maintenance after autologous stem cell transplants, has also ameliorated clinical results. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Gozzetti, Alessandro, Raspadori, Donatella, Bacchiarri, Francesca, Sicuranza, Anna, Pacelli, Paola, Ferrigno, Ilaria, Tocci, Dania, Bocchia, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565263/
https://www.ncbi.nlm.nih.gov/pubmed/32927719
http://dx.doi.org/10.3390/jpm10030120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565263/
https://www.ncbi.nlm.nih.gov/pubmed/32927719
http://dx.doi.org/10.3390/jpm10030120

Ejemplares similares